(lp0
S'ArQule Inc. ARQL  Wall Street Journal - Feb 12, 2011 News ArQule Inc.ARQL. Significant News Only. 01/05/17; Press Release. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist.'
p1
aS"ArQule, Inc.  Shares Dive as HCC Trial Fails to Meet Primary Endpoint Smarter Analyst - Feb 17, 2017 ArQule, Inc.  shares tumbled nearly 20% this morning after investors learned that the company's METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma  did not meet its primary endpoint of improving overall survival."
p2
aS"ArQule, Inc. 's Liver Cancer Drug Fails: What's Next? Market Exclusive - Feb 20, 2017 ArQule, Inc.  took a real hit at the end of last week, as the company announced data from a late stage oncology trial.ArQule Liver Cancer Drug Fails Phase 3  - InvestopediaTwo Stocks on Trader's Radar: ArQule Inc. , Dean Foods Company ... - The Newburgh Press"
p3
aS'ArQule Is Undervalued Going Into Catalyst Events Seeking Alpha - Oct 21, 2016 ArQule  is a small biopharmaceutical company  engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.'
p4
aS'ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Yahoo Finance - Mar 7, 2017 ArQule, Inc.  today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016, the Company reported a net loss of $6,820,000 or $0.10 per share, compared with net loss of $2,852,000 or ...'
p5
aS'Annual Global Healthcare Conference on February 15, 2017 Business Wire  - Feb 8, 2017 BURLINGTON, Mass.----ArQule, Inc.  today announced that Paolo Pucci, Chief Executive Officer, and Dr.'
p6
aS'ArQule, Inc.  to Post FY2018 Earnings of  Per Share, Leerink ... Sports Perspectives - 17 hours ago ArQule logo ArQule, Inc.  - Leerink Swann decreased their FY2018 earnings per share estimates for shares of ArQule in a report released on Wednesday.Prepping for a Big Move? Share Update on ArQule, Inc.  - Morgan Research'
p7
aS'ArQule, Inc.  Upgraded by Zacks Investment Research to Hold Chaffey Breeze - Mar 9, 2017 ArQule, Inc. logo Zacks Investment Research upgraded shares of ArQule, Inc.  from a sell rating to a hold rating in a research note published on Wednesday morning.Noteworthy Stock to Observe: ArQule, Inc.  - Is storiesArQule, Inc.  Upgraded to Hold at Zacks Investment Research - BBNS'
p8
aS"Sell-Side Analyst's Predictions: ArQule, Inc. , Array BioPharma Inc.  The USA Commerce - Feb 21, 2017 Shares of ArQule, Inc.  dropped -18.37% to $1.20. During the trading on 02/17/2017, Company's stock ranged from $1.13 to $1.26."
p9
aS'Leerink Swann Analysts Reduce Earnings Estimates for ArQule, Inc.  The Cerbat Gem - Mar 14, 2017 ArQule logo ArQule, Inc.  - Stock analysts at Leerink Swann decreased their FY2018 EPS estimates for ArQule in a research report issued to clients and investors on Wednesday.ArQule, Inc.  Reviewed By Analysts - The De Soto Edge'
p10
a.